From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer
Abstract
:Simple Summary
Abstract
1. Oncogenesis
2. Introduction to Prostate Cancer
3. PSMA and Prostate Cancer Diagnosis
4. PSMA PET Imaging
5. Theranostics
6. J591
7. 177. LuPSMA-617
8. 177. Lu-PSMA-I&T
9. Ra-223
10. Ac-225
11. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Boveri, T.; Boveri, M. The origin of malignant tumors. 1929. Available online: https://cir.nii.ac.jp/crid/1130000794960007168 (accessed on 30 July 2024).
- Yamagiwa, K.; Ichikawa, K. Experimental study of the pathogenesis of carcinoma. J. Cancer Res. 1918, 3, 1–29. [Google Scholar] [CrossRef] [PubMed]
- Watson, J.D.; Crick, F.H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953, 171, 737–738. [Google Scholar] [CrossRef] [PubMed]
- Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921, Erratum in Nature 2001, 411, 720; Erratum in Nature 2001, 412, 565.. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [PubMed]
- Brown, J.S.; Amend, S.R.; Austin, R.H.; Gatenby, R.A.; Hammarlund, E.U.; Pienta, K.J. Updating the Definition of Cancer. Mol Cancer Res. 2023;21(11):1142-1147. [CrossRef]
- Kontomanolis, E.N.; Koutras, A.; Syllaios, A.; Schizas, D.; Mastoraki, A.; Garmpis, N.; Diakosavvas, M.; Angelou, K.; Tsatsaris, G.; Pagkalos, A.; et al. Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer. Res. 2020, 40, 6009–6015. [Google Scholar] [CrossRef]
- Zack, T.I.; Schumacher, S.E.; Carter, S.L.; Cherniack, A.D.; Saksena, G.; Tabak, B.; Lawrence, M.S.; Zhsng, C.-Z.; Wala, J.; Mermel, C.H.; et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 2013, 45, 1134–1140. [Google Scholar] [CrossRef]
- Qiu, X.; Boufaied, N.; Hallal, T.; Cherniack, A.D.; Saksena, G.; Tabak, B.; Lawrence, M.S.; Zhang, C.Z.; Wala, J.; Mermel, C.H.; et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat. Commun. 2022, 13, 2559. [Google Scholar] [CrossRef]
- Cooper, G.M. Tumor suppressor genes. In The Cell: A Molecular Approach, 2nd ed.; Sinauer Associates: Sunderland, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK9894/ (accessed on 30 July 2024).
- Palma, M.; Ristori, E.; Ricevuto, E.; Giannini, G.; Gulino, A. BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Crit. Rev. Oncol. Hematol. 2006, 57, 1–23. [Google Scholar] [CrossRef]
- Kew, M.C. Aflatoxins as a cause of hepatocellular carcinoma. J. Gastrointestin Liver Dis. 2013, 22, 305–310. [Google Scholar]
- Ilango, S.; Paital, B.; Jayachandran, P.; Padma, P.R.; Nirmaladevi, R. Epigenetic alterations in cancer. Front. Biosci. 2020, 25, 1058–1109. [Google Scholar] [CrossRef]
- International Agency for Research on Cancer. Mechanisms of Carcinogenesis. Available online: https://www.iarc.who.int/wp-content/uploads/2018/07/wcr_2008_5.pdf (accessed on 17 June 2024).
- Mattiuzzi, C.; Lippi, G. Current Cancer Epidemiology. J. Epidemiol. Glob. Health 2019, 9, 217–222. [Google Scholar] [CrossRef] [PubMed]
- Wani, M.; Madaan, S. What Is New in the Management of High-Risk Localized Prostate Cancer? J. Clin. Med. 2023, 12, 455. [Google Scholar] [CrossRef]
- Dasgupta, P.; Baade, P.D.; Aitken, J.F.; Ralph, N.; Chambers, S.K.; Dunn, J. Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. Front. Oncol. 2019, 9, 238. [Google Scholar] [CrossRef] [PubMed]
- Tonon, L.; Fromont, G.; Boyault, S.; Thomas, E.; Ferrari, A.; Sertier, A.S.; Kielbassa, J.; Le Texier, V.; Kamoun, A.; Elarouci, N.; et al. Mutational profile of aggressive, localized prostate cancer from African Caribbean men versus European ancestry men. Eur. Urol. 2019, 75, 11–15. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Wang, G.; Zhao, D.; Spring, D.J.; DePinho, R.A. Genetics and biology of prostate cancer. Genes Dev. 2018, 32, 1105–1140. [Google Scholar] [CrossRef]
- Ma, B.; Wells, A.; Wei, L.; Zheng, J. Prostate cancer liver metastasis: Dormancy and resistance to therapy. Semin. Cancer Biol. 2020, 71, 2–9. [Google Scholar] [CrossRef]
- Lam, T.; Birzniece, V.; McLean, M.; Gurney, H.; Hayden, A.; Cheema, B.S. The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training. Sports Med. Open 2020, 6, 13–14. [Google Scholar] [CrossRef]
- Martin, P.; Liu, Y.N.; Pierce, R.; Abou-Kheir, W.; Casey, O.; Seng, V.; Camacho, D.; Simpson, R.M.; Kelly, K. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am. J. Pathol. 2011, 179, 422–435. [Google Scholar] [CrossRef]
- Georgescu, M.M. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 2010, 1, 1170–1177. [Google Scholar] [CrossRef]
- Ozaki, T.; Nakagawara, A. Role of p53 in Cell Death and Human Cancers. Cancers 2011, 3, 994–1013. [Google Scholar] [CrossRef] [PubMed]
- Duan, R.; Du, W.; Guo, W. EZH2: A novel target for cancer treatment. J. Hematol. Oncol. 2020, 13, 104. [Google Scholar] [CrossRef]
- Conteduca, V.; Hess, J.; Yamada, Y.; Ku, S.Y.; Beltran, H. Epigenetics in prostate cancer: Clinical implications. Transl. Androl. Urol. 2021, 10, 3104–3116. [Google Scholar] [CrossRef] [PubMed]
- Trewartha, D.; Carter, K. Advances in prostate cancer treatment. Nat. Rev. Drug Discov. 2013, 12, 823–824. [Google Scholar] [CrossRef]
- Perry, E.; Talwar, A.; Taubman, K.; Ng, M.; Wong, L.M.; Booth, R.; Sutherland, T.R. [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2038–2046. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Zelchan, R.; Orlova, A. The performance of FDA-approved PET imaging agents in the detection of prostate cancer. Biomedicines 2022, 10, 2533. [Google Scholar] [CrossRef]
- Cam, K.; Yucel, S.; Turkeri, L.; Akdas, A. Accuracy of transrectal ultrasound guided prostate biopsy: Histopathological correlation to matched prostatectomy specimens. Int. J. Urol. 2002, 9, 257–260. [Google Scholar] [CrossRef]
- Yacoub, J.H.; Verma, S.; Moulton, J.S.; Eggener, S.; Aytekin, O. Imaging-guided prostate biopsy: Conventional and emerging techniques. Radiographics 2012, 32, 819–837. [Google Scholar] [CrossRef]
- Yilmaz, E.C.; Shih, J.H.; Belue, M.J.; Harmon, S.A.; Phelps, T.E.; Garcia, C.; Hazen, L.A.; Toubaji, A.; Merino, M.J.; Gurram, S.; et al. Prospective evaluation of PI-RADS Version 2.1 for prostate cancer detection and investigation of multiparametric MRI-derived markers. Radiology 2023, 307, e221309. [Google Scholar] [CrossRef]
- Contractor, K.; Challapalli, A.; Barwick, T.; Winkler, M.; Hellawell, G.; Hazell, S.; Tomasi, G.; Al-Nahhas, A.; Mapelli, P.; Kenny, L.M.; et al. Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin. Cancer Res. 2011, 17, 7673–7683. [Google Scholar] [CrossRef]
- Graziani, T.; Ceci, F.; Castellucci, P.; Polverari, G.; Lima, G.M.; Lodi, F.; Morganti, A.G.; Ardizzoni, A.; Schiavina, R.; Fanti, S. 11C-choline PET/CT for restaging prostate cancer: Results from 4,426 scans in a single-centre patient series. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1971–1979. [Google Scholar] [CrossRef]
- Treglia, G.; Pereira Mestre, R.; Ferrari, M.; Bosetti, D.G.; Pascale, M.; Oikonomou, E.; De Dosso, S.; Jermini, F.; Prior, J.O.; Roggero, E.; et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: A meta-analysis. Am. J. Nucl. Med. Mol. Imaging 2019, 9, 127–139. [Google Scholar] [PubMed]
- Filippi, L.; Bagni, O.; Crisafulli, C.; Cerio, I.; Brunotti, G.; Chiaravalloti, A.; Schillaci, O.; Dore, F. Detection rate and clinical impact of PET/CT with 18F-FACBC in patients with biochemical recurrence of prostate cancer: A retrospective bicentric study. Biomedicines 2022, 10, 177. [Google Scholar] [CrossRef] [PubMed]
- Thoeny, H.C.; Froehlich, J.M.; Triantafyllou, M.; Huesler, J.; Bains, L.J.; Vermathen, P.; Fleischmann, A.; Studer, U.E. Metastases in normal-sized pelvic lymph nodes: Detection with diffusion-weighted MR imaging. Radiology 2014, 273, 125–135. [Google Scholar] [CrossRef] [PubMed]
- Uijen, M.J.M.; Derks, Y.H.W.; Merkx, R.I.J.; Scilham, M.G.M.; Roosen, J.; Privé, B.M.; van Lith, S.A.M.; van Herpen, C.M.L.; Gotthardt, M.; Heskamp, S.; et al. PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4350–4368. [Google Scholar] [CrossRef] [PubMed]
- Adnan, A.; Basu, S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics 2023, 13, 158. [Google Scholar] [CrossRef]
- Roberts, M.J.; Maurer, T.; Perera, M.; Eiber, M.; Hope, T.A.; Ost, P.; Siva, S.; Hofman, M.S.; Murphy, D.G.; Emmett, L.; et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat. Rev. Urol. 2023, 20, 23–47. [Google Scholar] [CrossRef]
- Pellegrino, S.; Fonti, R. A look into the future: The role of PSMA beyond prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2023, 51, 278–280. [Google Scholar] [CrossRef]
- Piron, S.; Verhoeven, J.; De Coster, E.; Descamps, B.; Kersemans, K.; Pieters, L.; Vral, A.; Vanhove, C.; De Vos, F. Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer. Sci Rep. 2021;11(1):22623. [CrossRef]
- Ghosh, A.; Heston, W.D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 2004, 91, 528–539. [Google Scholar] [CrossRef]
- Ross, J.S.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P., Jr.; Kaur, P.; Gray, K.; Webb, I.; Gray, G.S.; Mosher, R.; Kallakury, B.V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9, 6357–6362. [Google Scholar]
- Reddy, V.; Hwang, C.; Reddy, G.P.; Kim, S.H. A Novel Role of Prostate-Specific Membrane Antigen in Telomere Stability in Prostate Cancer Cells. Mol. Cancer Res. 2023, 21, 1176–1185. [Google Scholar] [CrossRef] [PubMed]
- Hong, X.; Mao, L.; Xu, L.; Hu, Q.; Jia, R. Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes. Bioengineered 2022, 13, 995–1012. [Google Scholar] [CrossRef] [PubMed]
- Kaittanis, C.; Andreou, C.; Hieronymus, H.; Mao, N.; Foss, C.A.; Eiber, M.; Weirich, G.; Panchal, P.; Gopalan, A.; Zurita, J.; et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates onco-genic signaling through metabotropic glutamate receptors. J. Exp. Med. 2018, 215, 159–175. [Google Scholar] [CrossRef] [PubMed]
- Yao, V.; Berkman, C.E.; Choi, J.K.; O’Keefe, D.S.; Bacich, D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 2010, 70, 305–316. [Google Scholar] [CrossRef] [PubMed]
- Yao, V.; Bacich, D.J. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 2006, 66, 867–875. [Google Scholar] [CrossRef]
- Affronti, H.C.; Rowsam, A.M.; Pellerite, A.J.; Rosario, S.R.; Long, M.D.; Jacobi, J.J.; Bianchi-Smiraglia, A.; Boerlin, C.S.; Gillard, B.M.; Karasik, E. Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy. Nat. Commun. 2020, 11, 52. [Google Scholar] [CrossRef]
- Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A.; Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486–495. [Google Scholar] [CrossRef]
- Surasi, D.S.; Eiber, M.; Maurer, T.; Preston, M.A.; Helfand, B.T.; Josephson, D.; Tewari, A.K.; Somford, D.M.; Rais-Bahrami, S.; Koontz, B.F.; et al. Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavorable intermediate- to very-high-risk prostate cancer: Results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur. Urol. 2023, 84, 361–370. [Google Scholar] [CrossRef]
- Jani, A.B.; Ravizzini, G.C.; Gartrell, B.A.; Siegel, B.A.; Twardowski, P.; Saltzstein, D.; Fleming, M.T.; Chau, A.; Davis, P.; Chapin, B.F.; et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT). J. Urol. 2023, 210, 299–311. [Google Scholar] [CrossRef]
- Jochumsen, M.R.; Bouchelouche, K. PSMA PET/CT imaging in prostate cancer: Impact on clinical management and patient outcomes. Clin. Nucl. Med. 2024, 49, 1–10. [Google Scholar]
- Houshmand, S.; Salavati, A.; Solnes, L.B. Clinical applications of PSMA PET in prostate cancer management. PET Clin. 2023, 18, 1–18. [Google Scholar]
- Fendler, W.P.; Calais, J.; Eiber, M.; Flavell, R.R.; Rettig, M.B. PSMA PET for prostate cancer imaging: The current status and future directions. J. Nucl. Med. 2023, 64, 28–37. [Google Scholar]
- Morigi, J.J.; Stricker, P.D.; van Leeuwen, P.J.; Tang, R.; Ho, B.; Nguyen, Q.A.; Hruby, G.; Fogarty, G.; Jagavkar, R.; Kneebone, A.; et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients with rising PSA after curative treatment, being considered for targeted therapy. J. Nucl. Med. 2015, 56, 1185–1190. [Google Scholar] [CrossRef] [PubMed]
- Ashfar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C.; et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 610–617. [Google Scholar]
- Eiber, M.; Maurer, T.; Souvatzoglou, M.; Beer, A.J.; Ruffani, A.; Haller, B.; Graner, F.-P.; Kübler, H.; Haberhorn, U.; Eisenhut, M.; et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2016, 56, 668–674. [Google Scholar] [CrossRef] [PubMed]
- Castellucci, P.; Ceci, F.; Fanti, S.; Picchio, M. PET/CT in recurrent prostate cancer: Focus on PSA kinetics and therapeutic decisions. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1460–1473. [Google Scholar]
- Krause, B.J.; Souvatzoglou, M.; Tuncel, M.; Herrmann, K.; Buck, A.K.; Grosu, A.L. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 18–23. [Google Scholar] [CrossRef]
- Hope, T.A.; Afshar-Oromieh, A.; Eiber, M.; Emmett, L.; Fendler, W.P.; Lawhn-Heath, C.; Rowe, S.P. Imaging prostate cancer with prostate-specific membrane antigen PET/CT and PET/MRI: Current and future applications. AJR Am J Roentgenol. 2018;211(2):286-294. [CrossRef]
- Aggarwal, R.; Wei, X.; Kim, W.; Small, E.J.; Ryan, C.J.; Carroll, P.; Cooperberg, M.; Evans, M.J.; Hope, T. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur. Urol. Oncol. 2018, 1, 78–82. [Google Scholar] [CrossRef]
- Hope, T.A.; Truillet, C.; Ehman, E.C.; Afshar-Oromieh, A.; Aggarwal, R.; Ryan, C.J.; Carroll, P.R.; Small, E.J.; Evans, M.J. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: First human experience. J. Nucl. Med. 2017, 58, 81–84. [Google Scholar] [CrossRef]
- Ettala, O.; Malaspina, S.; Tuokkola, T.; Luoto, P.; Löyttyniemi, E.; Boström, P.J.; Kemppainen, J. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 665–673. [Google Scholar] [CrossRef]
- Tseng, J.-R.; Chang, S.-H.; Wu, Y.-Y.; Fan, K.-H.; Yu, K.-J.; Yang, L.-Y.; Hsiao, I.-T.; Liu, F.-Y.; Pang, S.-T. Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer—Results from a Pilot Prospective Study. Cancers 2022, 14, 1329. [Google Scholar] [CrossRef]
- Fanti, S.; Goffin, K.; Hadaschik, B.A.; Herrmann, K.; Maurer, T.; MacLennan, S.; Oprea-Lager, D.E.; Oyen, W.J.; Rouvière, O.; Mottet, N.; et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 469–476. [Google Scholar] [CrossRef]
- Shagera, Q.A.; Karfis, I.; Kristanto, P.; Spyridon, S.; Diamand, R.; Santapau, A.; Peltier, A.; Roumeguère, T.; Flamen, P.; Artigas, C. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. J. Nucl. Med. 2023, 64, 1869–1875. [Google Scholar] [CrossRef]
- Kaewput, C.; Vinjamuri, S. Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends. J. Clin. Med. 2022, 11, 2738. [Google Scholar] [CrossRef] [PubMed]
- Plouznikof, N.; Garcia, C.; Artigas, C.; Entezari, K.; Flamen, P. Heterogeneity of 68Ga-PSMA PET/CT uptake in fibrous dysplasia. Clin. Nucl. Med. 2019, 44, E593–E594. [Google Scholar] [CrossRef]
- Smith, S.E.; Murphey, M.D.; Motamedi, K.; Mulligan, M.E.; Resnik, C.S.; Gannon, F.H. From the archives of the AFIP. Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics 2002, 22, 1191–1216. [Google Scholar] [CrossRef]
- Zarzour, J.G.; Galgano, S.; McConathy, J.; Thomas, J.V.; Rais-Bahrami, S. Lymph node imaging in initial staging of prostate cancer: An overview and update. World J Radiol. 2017;9(10):389-399. [CrossRef]
- Hertz, S.; Roberts, A. Application of radioactive iodine in Graves disease. J. Clin. Investig. 1942, 21, 624. [Google Scholar]
- Seidlin, S.M.; Marinelli, L.D.; Oshry, E. Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 1946, 132, 838–847. [Google Scholar] [CrossRef] [PubMed]
- Verburg, F.A.; Heinzel, A.; Hänscheid, H.; Mottaghy, F.M.; Luster, M.; Giovanella, L. Nothing new under the nuclear sun: Towards 80 years of theranostics in nuclear medicine. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 199–201. [Google Scholar] [CrossRef]
- Sheikhbahaei, S.; Sadaghiani, M.S.; Rowe, S.P.; Solnes, L.B. Neuroendocrine tumor theranostics: An update and emerging applications in clinical practice. Am. J. Roentgenol. 2021, 217, 495–506. [Google Scholar] [CrossRef]
- Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 2017, 376, 125–135. [Google Scholar] [CrossRef] [PubMed]
- Uemura, M.; Watabe, T.; Hoshi, S.; Tanji, R.; Yaginuma, K.; Kojima, Y. The current status of prostate cancer treatment and PSMA theranostics. Ther. Adv. Med. Oncol. 2023, 15, 17588359231182293. [Google Scholar] [CrossRef] [PubMed]
- Salih, S.; Alkatheeri, A.; Alomaim, W.; Elliyanti, A. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges. Molecules 2022, 27, 5231. [Google Scholar] [CrossRef] [PubMed]
- Kassis, A.I.; Adelstein, S.J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46 (Suppl. S1), 4S–12S. [Google Scholar] [PubMed]
- Burkett, B.J.; Bartlett, D.J.; McGarrah, P.W.; Lewis, A.R.; Johnson, D.R.; Berberoğlu, K.; Pandey, M.K.; Packard, A.T.; Halfdanarson, T.R.; Hruska, C.B.; et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol. Imaging Cancer 2023, 5, e220157. [Google Scholar] [CrossRef]
- Ristau, B.T.; O’Keefe, D.S.; Bacich, D.J. The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research. Urol. Oncol. 2014, 32, 272–279. [Google Scholar] [CrossRef]
- Deb, N.; Goris, M.; Trisler, K.; Fowler, S.; Saal, J.; Ning, S.; Becker, M.; Marquez, C.; Knox, S. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 1996, 2, 1289–1297. [Google Scholar] [PubMed]
- Kahn, D.; Austin, J.C.; Maguire, R.T.; Miller, S.J.; Gerstbrein, J.; Williams, R.D. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother. Radiopharm. 1999, 14, 99–111. [Google Scholar] [CrossRef]
- Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J.; Bander, N.H. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22, 2522–2531. [Google Scholar] [CrossRef]
- Bander, N.H.; Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 2005, 23, 4591–4601. [Google Scholar] [CrossRef]
- Tagawa, S.T.; Milowsky, M.I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N.H.; Osborne, J.; Goldsmith, S.J.; Larson, S.; Taskar, N.P. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2013, 19, 5182–5191. [Google Scholar] [CrossRef] [PubMed]
- Tagawa, S.T.; Vallabhajosula, S.; Christos, P.J.; Jhanwar, Y.S.; Batra, J.S.; Lam, L.; Osborne, J.; Beltran, H.; Molina, A.M.; Goldsmith, S.J.; et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 2019, 125, 2561–2569. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, H.; Hird, K.; Cardaci, J.; Smith, S.; Lenzo, N.P. Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes. Mol. Diagn. Ther. 2024, 28, 291–299. [Google Scholar] [CrossRef]
- Telix Pharmaceuticals. PROSTACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability. Available online: https://telixpharma.com/news-views/prostact-select-study-of-tlx591-interim-readout-positive-results-confirm-safety-and-tolerability/#_ftn1 (accessed on 21 May 2024).
- Sartor, O.; de Bono, J.; Chi, K.N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S.T.; Nordquist, L.T.; Vaishampayan, N.; El-Haddad, G.; et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021, 385, 1091–1103. [Google Scholar] [CrossRef] [PubMed]
- Seifert, R.; Emmett, L.; Rowe, S.P.; Herrmann, K.; Hadaschik, B.; Calais, J.; Giesel, F.L.; Reiter, R.; Maurer, T.; Heck, M.; et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur. Urol. 2023, 83, 405–412. [Google Scholar] [CrossRef]
- Gafita, A.; Djaileb, L.; Rauscher, I.; Fendler, W.P.; Hadaschik, B.; Rowe, S.P.; Herrmann, K.; Calais, J.; Rettig, M.; Eiber, M.; et al. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology 2023, 308, e222148. [Google Scholar] [CrossRef]
- Farolfi, A.; Armstrong, W.R.; Djaileb, L.; Gafita, A.; Hotta, M.; Allen-Auerbach, M.; Unterrainer, L.M.; Fendler, W.P.; Rettig, M.; Eiber, M.; et al. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J. Nucl. Med. 2024, 65, 438–445. [Google Scholar] [CrossRef]
- Dhiantravan, N.; Emmett, L.; Joshua, A.M.; Pattison, D.A.; Francis, R.J.; Williams, S.; Sandhu, S.; Davis, I.D.; Vela, I.; Neha, N.; et al. UpFrontPSMA: A randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs. docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). BJU Int. 2021, 128, 331–342. [Google Scholar] [CrossRef]
- Eapen, R.S.; Buteau, J.P.; Jackson, P.; Mitchell, C.; Oon, S.F.; Alghazo, O.; McIntosh, L.; Dhiantravan, N.; Scalzo, M.J.; O’Brien, J.; et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur. Urol. 2024, 85, 217–226. [Google Scholar] [CrossRef]
- Hofman, M.S.; Violet, J.; Hicks, R.J.; Ferdinandus, J.; Thang, S.P.; Akhurst, T.; Iravani, A.; Kong, G.; Ravi Kumar, A.; Murphy, D.G.; et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study. Lancet Oncol. 2018, 19, 825–833. [Google Scholar] [CrossRef]
- Hofman, M.S.; Emmett, L.; Sandhu, S.; Iravani, A.; Buteau, J.P.; Joshua, A.M.; Goh, J.C.; Pattison, D.A.; Tan, T.H.; Kirkwood, I.D.; et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): Secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024, 25, 99–107. [Google Scholar] [CrossRef] [PubMed]
- Sartor, O.; Castellano Gauna, D.E.; Herrmann, K.; de Bono, J.S.; Shore, N.D.; Chi, K.N.N.; Crosby, M.; Piulats Rodriguez, J.M.; Flechon, A.; Wei, X.X.; et al. LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann. Oncol. 2023, 34 (Suppl. S2), S1324–S1325. [Google Scholar] [CrossRef]
- Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer. Lantheus Holdings. 18 December 2023. Available online: https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-and-point-biopharma-announce-positive-topline-results (accessed on 21 May 2024).
- Kluetz, P.G.; Pierce, W.; Maher, V.E.; Zhang, H.; Tang, S.; Song, P.; Liu, Q.; Haber, M.T.; Leutzinger, E.E.; Al-Hakim, A.; et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 2014, 20, 9–14. [Google Scholar] [CrossRef] [PubMed]
- Parker, C.; Nilsson, S.; Heinrich, D.; Helle, S.I.; O’Sullivan, J.M.; Fosså, S.D.; Chodacki, A.; Wiechno, P.; Logue, J.; Seke, M.; et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013, 369, 213–223. [Google Scholar] [CrossRef] [PubMed]
- Nindra, U.; Lin, P.; Becker, T.; Roberts, T.L.; Chua, W. Current state of theranostics in metastatic castrate-resistant prostate cancer. J. Med Imaging Radiat. Oncol. 2024, 68, 412–420. [Google Scholar] [CrossRef] [PubMed]
- Nilsson, S.; Larsen, R.H.; Fosså, S.D.; Balteskard, L.; Borch, K.W.; Westlin, J.E.; Salberg, G.; Bruland, O.S. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 2005, 11, 4451–4459. [Google Scholar] [CrossRef] [PubMed]
- Nilsson, S.; Franzén, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernäs, B.; Petersson, U.; Johannessen, D.C.; Sokal, M.; et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007, 8, 587–594. [Google Scholar] [CrossRef]
- Nilsson, S.; Strang, P.; Aksnes, A.K.; Franzèn, L.; Olivier, P.; Pecking, A.; Staffurth, J.; Vasanthan, S.; Andersson, C.; Bruland, Ø.S. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 2012, 48, 678–686. [Google Scholar] [CrossRef]
- Parker, C.C.; Pascoe, S.; Chodacki, A.; O’Sullivan, J.M.; Germá, J.R.; O’Bryan-Tear, C.G.; Haider, T.; Hoskin, P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur. Urol. 2013, 63, 189–197. [Google Scholar] [CrossRef]
- Higano, C.S.; George, D.J.; Shore, N.D.; Sartor, O.; Miller, K.; Conti, P.S.; Sternberg, C.N.; Saad, F.; Sade, J.P.; Bellmunt, J.; et al. Clinical outcomes and treatment patterns in REASSURE: Planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine 2023, 60, 101993. [Google Scholar] [CrossRef]
- Smith, M.; Parker, C.; Saad, F.; Miller, K.; Tombal, B.; Ng, Q.S.; Boegemann, M.; Matveev, V.; Piulats, J.M.; Zucca, L.E.; et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 408–419, Erratum in Lancet Oncol. 2019, 20, e559.. [Google Scholar] [CrossRef] [PubMed]
- Gourd, E. EMA guidance on radium-223 dichloride in prostate cancer. Lancet Oncol. 2018, 19, e190. [Google Scholar] [CrossRef] [PubMed]
- Maughan, B.L.; Kessel, A.; McFarland, T.R.; Sayegh, N.; Nussenzveig, R.; Hahn, A.W.; Hoffman, J.M.; Morton, K.; Sirohi, D.; Kohli, M.; et al. Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist 2021, 26, 1006-e2129. [Google Scholar] [CrossRef]
- Kratochwil, C.; Bruchertseifer, F.; Giesel, F.L.; Weis, M.; Verburg, F.A.; Mottaghy, F.; Kopka, K.; Apostolidis, C.; Haberkorn, U.; Morgenstern, A. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016, 57, 1941–1944. [Google Scholar] [CrossRef] [PubMed]
- Kratochwil, C.; Bruchertseifer, F.; Rathke, H.; Hohenfellner, M.; Giesel, F.L.; Haberkorn, U.; Morgenstern, A. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J. Nucl. Med. 2018, 59, 795–802. [Google Scholar] [CrossRef] [PubMed]
- Feuerecker, B.; Tauber, R.; Knorr, K.; Heck, M.; Beheshti, A.; Seidl, C.; Bruchertseifer, F.; Pickhard, A.; Gafita, A.; Kratochwil, C.; et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer after Failure of Lutetium-177-PSMA. Eur. Urol. 2021, 79, 343–350. [Google Scholar] [CrossRef]
- Khreish, F.; Ebert, N.; Ries, M.; Maus, S.; Rosar, F.; Bohnenberger, H.; Stemler, T.; Saar, M.; Bartholomä, M.; Ezziddin, S. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: Pilot experience. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 721–728. [Google Scholar] [CrossRef]
- Lawal, I.O.; Morgenstern, A.; Vorster, M.; Knoesen, O.; Mahapane, J.; Hlongwa, K.N.; Maserumule, L.C.; Ndlovu, H.; Reed, J.D.; Popoola, G.O.; et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 3581–3592. [Google Scholar] [CrossRef]
- Sathekge, M.; Bruchertseifer, F.; Vorster, M.; Lawal, I.O.; Knoesen, O.; Mahapane, J.; Davis, C.; Mdlophane, A.; Maes, A.; Mokoala, K.; et al. mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J. Nucl. Med. 2022, 63, 1496–1502. [Google Scholar] [CrossRef]
- Sathekge, M.; Bruchertseifer, F.; Vorster, M.; Lawal, I.O.; Mokoala, K.; Reed, J.; Maseremule, L.; Ndlovu, H.; Hlongwa, K.; Maes, A.; et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): Preliminary clinical findings. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 2210–2218. [Google Scholar] [CrossRef]
Clinical Trial Identifier/Authors | Study Objective | Phase | Status |
---|---|---|---|
Bander et al. [71] | 177Lu-J591 in androgen-independent prostate cancer | 1 | Complete |
NCT00195039 | 177Lu-J591 in mCRPC | 2 | Complete |
NCT00538668 | 177Lu-J591 in mCRPC | 1/2 | Complete |
NCCT04786847 (ProstACT SELECT) | 177Lu-TLX591 with SoC in mCRPC | 1 | Complete |
NCT05146973 (ProstACT Target) | 177Lu-TLX591 with external beam radiation therapy in biochemically recurrent, oligometastatic PSMA prostate cancer | 2 | Active, not recruiting |
NCT04876651 (PROSTACT) | 177Lu-TLX591 with Soc versus Soc alone in mCRPC | 3 | Not yet recruiting |
Criteria | Full Name | Details |
---|---|---|
RECIST | Response Evaluation Criteria in Solid Tumors | Evaluates tumors’ reactions to treatments by monitoring changes in their size through anatomical imaging techniques. It primarily focuses on measurable tumor lesions. |
PERCIST | PET Response Criteria in Solid Tumors | Assesses metabolic response to treatments using PET scans by monitoring changes in standardized uptake values (SUV) of tumors, emphasizing metabolic changes over size alterations. |
PCWG3 | Prostate Cancer Working Group 3 | Provides guidelines tailored to prostate cancer for assessing treatment response and disease progression by considering PSA levels, imaging results, and clinical status. |
PPP | PSMA PET Progression | Focuses on disease progression in PSMA PET, monitoring biochemical or clinical progression along with lesion counts observed through PSMA-ligand PET. |
RECIP | Response Evaluation Criteria in PSMA Imaging | Specifically designed for PSMA PET, these criteria evaluate treatment effectiveness in metastatic castration-resistant prostate cancer by focusing on new lesions and overall PSMA tumor volume changes. |
Clinical Trial Identifier/Authors | Study Objective | Phase | Status |
---|---|---|---|
VISION (NCT03511664) | 177Lu-PSMA-617 and Soc versus Soc alone in mCRPC | 3 | Complete |
UpfrontPSMA (NCT04343885) | 177Lu-PSMA-617 followed by docetaxel versus docetaxel | 2 | Active, not recruiting |
LuTectomy (NCT04430192) | 177Lu-PSMA-617 before radical prostatectomy and pelvic lymph node dissection | 1/2 | Active, not recruiting |
LuPSMA (ACTRN12615000912583) | 177Lu-PSMA-617 in mCRPC | 2 | Complete |
TheraP (NCT03392428) | 177Lu-PSMA617 versus cabazitaxel in mCRPC | 2 | Complete |
PSMAfore (NCT04689828) | 177Lu-PSMA-617 vs. change in ART in taxane-naïve mCRPC | 3 | Active, not recruiting |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hameed, M.Y.; Gul, M.; Chaudhry, A.; Muzaffar, H.; Sheikh, M.; Chee, W.; Ayyash, S.; Ayyash, J.; Al-Hindi, M.; Shahare, H.; et al. From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer. Cancers 2024, 16, 3039. https://doi.org/10.3390/cancers16173039
Hameed MY, Gul M, Chaudhry A, Muzaffar H, Sheikh M, Chee W, Ayyash S, Ayyash J, Al-Hindi M, Shahare H, et al. From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer. Cancers. 2024; 16(17):3039. https://doi.org/10.3390/cancers16173039
Chicago/Turabian StyleHameed, Muhammad Y., Maryam Gul, Abbas Chaudhry, Huma Muzaffar, Mubashir Sheikh, Winson Chee, Sondos Ayyash, Jenna Ayyash, Mohannad Al-Hindi, Humam Shahare, and et al. 2024. "From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer" Cancers 16, no. 17: 3039. https://doi.org/10.3390/cancers16173039